

**BIOVACSAFE Kick-Off Meeting
Final Agenda**

Weds 28th March 2012

17.00 Optional visit to brewery

Thu 29th March 2012

08.30 Registration & coffee

Introduction: Project Vision & Challenges

09.00 The BIOVACSAFE project & meeting objectives: David Lewis
The EFPIA perspective: Aldo Tagliabue
The IMI perspective: Maria-Teresa de Magistris

Morning sessions: Orientation to the project: short overviews of each activity:

Session 1: Technology Core. Chair: Arnaud Didierlaurent

09.25: Gene expression profiles: Stefan Kaufmann
09.35: Metabolomics: Intawat Nookaew
09.45: Stress Proteins & markers of regulatory T cell activity: Willem van Eden
09.55: Autoantibody profiling by autoantigen microarrays: Irun Cohen

Session 2: Clinical trials of biomarkers of inflammation. Chair: Pascalle Van Belle

10.05: Clinical trials for biomarkers of inflammation. David Lewis / Geert Lerous-Roels
10.20: On-going trials in other projects. Stephan Kaufmann/Peter Andersen

Session 3: WP2 - In vivo animal models and in vitro models. Chair: Sohail Ahmed

10.25: Task 1 & 2: Immune activation and inflammatory biomarkers in response to licensed vaccines, inflammatory stimuli and natural disease. Ali Harandi/Roger Legrand
10.35: Task 3. Impact of vaccination on biomarkers in disease "challenge". PeterAndersen/Robin Shattock
10.45: Task 4. Cross-validate human and preclinical biomarkers. Robin Shattock/ Ali Harandi

10.50 -11.10 : Coffee Break

Session 4: Populations & Clinical Cohorts (WPs 1, 3 & 4). Chair: Gary Chikami

11.10: Charité cohort in WPs 1, 3 & 4: Barbara Rath
11.25: ECUAVIDA cohort in WPs 1, 3 & 4: Phillip Cooper
11.40: Identification of novel sequence variants that associate with immune mediated adverse events (AE) and autoimmune diseases: Ingileif Jonsdottir
11.55: Autoantibody profiles of autoimmune disease: David Lewis

Session 5: Databases, guidelines & standardisation. Chair: Gary Chikami

12.00: WP5: Biovacsafe Data Management System and AEFI Assessment: Barbara Rath
12.10: WP5: IT solutions for DMS: Ingileif Jonsdottir
12.15: WP6 task 1: Development and Validation of biomarkers: Barry Walker
12.25: WP6 task 2: Task 2: Preparation guidelines and standardization: Barry Walker

12.35: General Discussion. Chair: Aldo Tagliabue

1300 - 1400 Lunch

Afternoon sessions: Sub-project planning & finalisation (1)

14.00 - 16.00: Internal sub-project meetings: session 1

WP1: Clinical trials: Chairs: Stefan Kaufmann / Ripley Ballou

WP2: Animal models: Chairs: Robin Shattock / Ernesto Oviedo-Orta

WP3 & 4: Autoimmunity: Chairs: Ingileif Jonsdottir/ Steven Black

16.00 - 16.15: Coffee Break

16.15 - 17.15: Feedback from sub-project discussions: session 1: Chair: Stefan Kaufmann

- WP1: Clinical trials: Stefan Kaufmann / Ripley Ballou
- WP2: Animal models: Robin Shattock / Sohail Ahmed
- WP3 & 4: Autoimmunity: Ingileif Jonsdottir/ Steven Black
- **General discussion.**

20.30 Social Dinner

Fri 30th March 2012

Session 1: Sub-project planning & finalisation (2)

08.30 - 09.30: Internal sub-project meetings: session 2. Chair: Barry Walker

WP5: DMS: Barbara Rath / Emanuelle Trannoy

WP6: Standards & Guidelines: Barry Walker / Gary Chikami

09.30 - 10.00: Feedback & discussion.

Session 2: Project management, finance, governance, communication

10.00: Project management, finance, governance: Lisa Hadden BIOVACSAFE Project Manager.

10.20: Dissemination & communication: Donata Medaglini

10.30: General discussion on project management, legal, regulatory etc.

11.00: Coffee break

11.15: Final discussion and plan of action: Chairs: David Lewis & Aldo Tagliabue

12.00: Steering Committee Meeting

13.00: Conclusion of meeting & lunch

DLML

version 22 Mar 2012